Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose recombinant versus standard-dose quadrivalent influenza vaccine in adults with severe obesity
2021-002691-39Phase 3Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Apr 2022
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of Quadrivalent recombinant influenza vaccine and Vaxigrip in influenza (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Started Apr 2022; status: active.
02
Drugs
Quadrivalent recombinant influenza vaccineVaxigrip
03
Conditions
influenza
Beyond the preview
Go deeper on 2021-002691-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002691-39.